122957-45-3

Basic information

• Product Name: 2,6-dimethyl-3-nitro-4(1H)-pyridone
• CAS NO: 122957-45-3
• Molecular Weight: 168.152
• Mol File: 122957-45-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2,6-dimethyl-3-nitro-4(1H)-pyridone(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dimethyl-3-nitro-4(1H)-pyridone(122957-45-3)
• EPA Substance Registry System: 2,6-dimethyl-3-nitro-4(1H)-pyridone(122957-45-3)

Safety Data

• Hazardous Substances Data: 122957-45-3(Hazardous Substances Data)

Usage

General Description

2,6-dimethyl-3-nitro-4(1H)-pyridone is a chemical compound with the molecular formula C7H8N2O3. It is a derivative of pyridone, an aromatic heterocyclic organic compound. This chemical has a nitro group and two methyl groups attached to the pyridone ring. It is commonly used as a precursor for the synthesis of various pharmaceuticals, agrochemicals, and other fine chemicals. The compound exhibits moderate acidity and can participate in various chemical reactions, making it a versatile building block for the synthesis of complex organic molecules. It is also known for its potential biological activity, and research is ongoing to explore its potential as a drug candidate for various therapeutic applications.

Upstream product

• 92247-78-4 1-benzyl-2,6-dimethyl-1H-pyridin-4-one 
• 7516-31-6 2,6-dimethyl-1H-pyridin-4-one 
• 1004-36-0 2,6-dimethylpyrone 

Downstream Products

• 15513-48-1 4-chloro-2,6-dimethyl-3-nitropyridine 

Relevant articles and documents

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatmen

Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 3. Discovery of a novel series of N-alkyl-N-[(fluorophenoxy)benzyl]-N'-arylureas with weak toxicological effects on adrenal glands

A series of N-alkyl-N-[(fluorophenoxy)benzyl]-N'-arylureas were prepared and evaluated for their ability to inhibit intestinal acyl-CoA:cholesterol O- acyltransferase and to inhibit accumulation of cholesteryl esters in macrophages in vitro. In vivo hypocholesterolemic activity was assessed in cholesterol-fed rats by oral administration as a dietary admixture and/or by gavage in a PEG400 vehicle. Modification of the alkyl substituent on the N'- aryl moiety and on the urea nitrogen significantly influenced macrophage assay in vitro. Toxicological study revealed a distinct relationship between macrophage assay and the toxicity observed in adrenal glands of rabbits treated with representatives of this series of compounds. Investigations utilizing the macrophage assay as an indicator for adrenal toxicity led to the identification of compounds 1g (FR190809) and 1k (FR186485, or FR195249 as its hydrochloride salt) as potent, nonadrenotoxic, orally efficacious ACAT inhibitors irrespective of the administration method.

Platelet activating factor antagonists

Platelet activating factor antagonists of formula (I): STR1 wherein R is phenyl or phenyl substituted by one or more substituents selected from nitro, halo, C1 -C4 alkyl, C1 -C4 alkoxy, aryl (C1 -C4) alkoxy, fluoro (C1 -C4) alkoxy, C1 -C4 alkylthio, C1 -C4 alkylsulphonyl, hydroxy, trifluoromethyl and cyano, or is phenyl fused to a dioxole ring; R1 and R2 are each independently H or C1 -C6 alkyl, or R1 and R2 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl, N-(C1 -C4 alkyl) piperazinyl or N-(C2 -C4 alkanoyl)-piperazinyl group; or R2 is H or C1 -C4 alkyl and R1 is CN, C3 -C7 cycloalkyl, aryl, heteroaryl or a C1 -C4 alkyl group substituted by one or more substituents selected from C3 -C7 cycloalkyl, C1 -C4 alkoxycarbonyl, aryl or heteroaryl; Z is selected from C1 -C6 alkoxy, aryl (C1 -C4) alkoxy, hydroxy, and --NR4 R5 wherein each of R4 and R5 is independently H or C1 -C6 alkyl, or R4 and R5 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl or N-(C1 -C4 alkyl) piperazinyl group; Y is 1,4 phenylene or pyridine-2,5-diyl, and X is a 5 or 6 membered aromatic heterocyclic group containing one or more nitrogen atoms in its ring; which ring may be fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, at least one of said heterocyclic rings optionally also containing an oxygen or sulphur atom, and being optionally substituted with one or more substituents selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo, CF3 and CN; and their pharmaceutically acceptable salts.